CD274 and hypothyroidism: Moreover, the incidence of other common treatment-related adverse events such as hypothyroidism and hyperthyroidism, which were the most frequent endocrine immune-related adverse events for PD-1/PD-L1 inhibitor alone, must be considered [67].